GMDA - Gamida's rises 5% after cell therapy candidate GDA-501 shows promising antitumor activity against HER2+ cancers
- Gamida Cell ( NASDAQ: GMDA ) on Monday announced positive data from its cell therapy candidate, GDA-501, to treat cancer.
- ( GMDA ) has risen ~5.4% before the bell.
- GDA-501, with NAM technology has shown successful expansion of natural killer cells, enhanced functionality, increased cytotoxic activity as well as creating a protective effect against oxidative stress and improved homing to targeted blood and solid tumor cancers, the company said.
- "These results suggest that GDA-501 represents a unique allogeneic cell therapy candidate potentially targeting HER2+ solid tumors," said Yona Geffen, Research and Development at Gamida Cell.
- Immune cell therapies have been limited in solid tumors due to multiple barriers, including immunosuppressive tumor microenvironment, inefficient trafficking, and heterogeneity of tumor antigens.
For further details see:
Gamida's rises 5% after cell therapy candidate GDA-501 shows promising antitumor activity against HER2+ cancers